Verónica Ayllón

Verónica Ayllón

Auto-generated profile, based on publicly available information

Verónica Ayllón

Gene Regulation, Stem Cells and Development Group, Department of Genomic Oncology, GENYO - Centre for Genomics and Oncological Research, Pfizer, University of Granada, Junta de Andalucía, PTS, Granada 18016, Granada, Spain

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

15 May 2000 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
VAVerónica Ayllón
Verónica Ayllón
CMCarlos Martínez‐A
Carlos Martínez‐A
AGAlphonse García
Alphonse García
XCXavier Cayla
Xavier Cayla
RARebollo Angelita
Rebollo Angelita
Growth factor deprivation is a physiological mechanism to regulate cell death. We utilize an interleukin‐2 (IL‐2)‐dependent murine T‐cell line to identify proteins that interact with Bad upon IL‐2 stimulation or deprivation. Using the yeast two‐hybrid system, glutathione S‐transferase (GST) fusion proteins and co‐immunoprecipitation techniques, we found that Bad interacts with protein phosphatase 1α (PP1α). Serine phosphorylation of Bad is induced by IL‐2 and its dephosphorylation correlates with appearance of apoptosis. IL‐2 deprivation induces Bad dephosphorylation, suggesting the involvement of a serine phosphatase. A serine/threonine phosphatase activity, sensitive to the phosphatase inhibitor okadaic acid, was detected in Bad immunoprecipitates from IL‐2‐stimulated cells, increasing after IL‐2 deprivation. This enzymatic activity also dephosphorylates in vivo32P‐labeled Bad. Treatment of cells with okadaic acid blocks Bad dephosphorylation and prevents cell death. Finally, Ras activation controls the catalytic activity of PP1α. These results strongly suggest that Bad is an in vitro and in vivo substrate for PP1α phosphatase and that IL‐2 deprivation‐induced apoptosis may operate by regulating Bad phosphorylation through PP1α phosphatase, whose enzymatic activity is regulated by Ras.

13 November 2014 in Blood
Verified
Journal Article
Open access
PDF file
VRVeronica Ramos-Mejia
Veronica Ramos-Mejia
ONOscar Navarro-Montero
Oscar Navarro-Montero
VAVerónica Ayllón
Verónica Ayllón
CBClara Bueno
Clara Bueno
TRTamara Romero
Tamara Romero
PMPablo Menendez
Pablo Menendez
The molecular determinants regulating the specification of human embryonic stem cells (hESCs) into hematopoietic cells remain elusive. HOXA9 plays a relevant role in leukemogenesis and hematopoiesis. It is highly expressed in hematopoietic stem and progenitor cells (HSPCs) and is downregulated upon differentiation. Hoxa9-deficient mice display impaired hematopoietic development, and deregulation of HOXA9 expression is frequently associated with acute leukemia. Analysis of the genes differentially expressed in cord blood HSPCs vs hESC-derived HSPCs identified HOXA9 as the most downregulated gene in hESC-derived HSPCs, suggesting that expression levels of HOXA9 may be crucial for hematopoietic differentiation of hESC. Here we show that during hematopoietic differentiation of hESCs, HOXA9 expression parallels hematopoietic development, but is restricted to the hemogenic precursors (HEP) (CD31+CD34+CD45−), and diminishes as HEPs differentiate into blood cells (CD45+). Different gain-of-function and loss-of-function studies reveal that HOXA9 enhances hematopoietic differentiation of hESCs by specifically promoting the commitment of HEPs into primitive and total CD45+ blood cells. Gene expression analysis suggests that nuclear factor-κB signaling could be collaborating with HOXA9 to increase hematopoietic commitment. However, HOXA9 on its own is not sufficient to confer in vivo long-term engraftment potential to hESC-hematopoietic derivatives, reinforcing the idea that additional molecular regulators are needed for the generation of definitive in vivo functional HSPCs from hESC.

5 May 2011 in Blood
Verified
Journal Article
Open access
PDF file
RMRosa Montes
Rosa Montes
VAVerónica Ayllón
Verónica Ayllón
IGIvan Gutierrez-Aranda
Ivan Gutierrez-Aranda
IPIsidro Prat
Isidro Prat
MHM. Carmen Hernández-Lamas
M. Carmen Hernández-Lamas
PMPablo Menendez
Pablo Menendez
Infant acute lymphoblastic leukemia harboring the fusion mixed-lineage leukemia (MLL)-AF4 is associated with a dismal prognosis and very brief latency. Our limited understanding of transformation by MLL-AF4 is reflected in murine models, which do not accurately recapitulate the human disease. Human models for MLL-AF4 disease do not exist. Hematopoietic stem or progenitor cells (HSPCs) represent probable targets for transformation. Here, we explored in vitro and in vivo the impact of the enforced expression of MLL-AF4 in human cord blood-derived CD34+ HSPCs. Intrabone marrow transplantation into NOD/SCID-IL2Rγ−/− mice revealed an enhanced multilineage hematopoietic engraftment, efficiency, and homing to other hematopoietic sites on enforced expression of MLL-AF4. Lentiviral transduction of MLL-AF4 into CD34+ HSPCs increased the in vitro clonogenic potential of CD34+ progenitors and promoted their proliferation. Consequently, cell cycle and apoptosis analyses suggest that MLL-AF4 conveys a selective proliferation coupled to a survival advantage, which correlates with changes in the expression of genes involved in apoptosis, sensing DNA damage and DNA repair. However, MLL-AF4 expression was insufficient to initiate leukemogenesis on its own, indicating that either additional hits (or reciprocal AF4-MLL product) may be required to initiate ALL or that cord blood-derived CD34+ HSPCs are not the appropriate cellular target for MLL-AF4-mediated ALL.

1 July 2012 in Molecular Therapy
Verified
Journal Article
Open access
PRPedro Jose Real
Pedro Jose Real
GLGertrudis Ligero
Gertrudis Ligero
VAVeronica Ayllon
Veronica Ayllon
VRVeronica Ramos-Mejia
Veronica Ramos-Mejia
CBClara Bueno
Clara Bueno
PMPablo Menendez
Pablo Menendez
Determining the molecular regulators/pathways responsible for the specification of human embryonic stem cells (hESCs) into hematopoietic precursors has far-reaching implications for potential cell therapies and disease modeling. Mouse models lacking SCL/TAL1 (stem cell leukemia/T-cell acute lymphocytic leukemia 1) do not survive beyond early embryogenesis because of complete absence of hematopoiesis, indicating that SCL is a master early hematopoietic regulator. SCL is commonly found rearranged in human leukemias. However, there is barely information on the role of SCL on human embryonic hematopoietic development. Differentiation and sorting assays show that endogenous SCL expression parallels hematopoietic specification of hESCs and that SCL is specifically expressed in hematoendothelial progenitors (CD45−CD31+CD34+) and, to a lesser extent, on CD45+ hematopoietic cells. Enforced expression of SCL in hESCs accelerates the emergence of hematoendothelial progenitors and robustly promotes subsequent differentiation into primitive (CD34+CD45+) and total (CD45+) blood cells with higher clonogenic potential. Short-hairpin RNA–based silencing of endogenous SCL abrogates hematopoietic specification of hESCs, confirming the early hematopoiesis-promoting effect of SCL. Unfortunately, SCL expression on its own is not sufficient to confer in vivo engraftment to hESC-derived hematopoietic cells, suggesting that additional yet undefined master regulators are required to orchestrate the stepwise hematopoietic developmental process leading to the generation of definitive in vivo functional hematopoiesis from hESCs.

1 January 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KOKatie M. O'CAllaghan
Katie M. O'CAllaghan
VAVeronica Ayllon
Veronica Ayllon
JOJean O'KEeffe
Jean O'KEeffe
YWYanru Wang
Yanru Wang
OCOrla T. Cox
Orla T. Cox
Rosemary O’ConnorRosemary O’Connor
Rosemary O’Connor
Endocytosis and trafficking of receptors and nutrient transporters are dependent on an acidic intra-endosomal pH that is maintained by the vacuolar H+-ATPase (V-ATPase) proton pump. V-ATPase activity has also been associated with cancer invasiveness. Here, we report on a new V-ATPase-associated protein, which we identified in insulin-like growth factor I (IGF-I) receptor-transformed cells, and which was separately identified in Caenorhabditis elegans as HRG-1, a member of a family of heme-regulated genes. We found that HRG-1 is present in endosomes but not in lysosomes, and it is trafficked to the plasma membrane upon nutrient withdrawal in mammalian cells. Suppression of HRG-1 with small interfering RNA causes impaired endocytosis of transferrin receptor, decreased cell motility, and decreased viability of HeLa cells. HRG-1 interacts with the c subunit of the V-ATPase and enhances V-ATPase activity in isolated yeast vacuoles. Endosomal acidity and V-ATPase assembly are decreased in cells with suppressed HRG-1, whereas transferrin receptor endocytosis is enhanced in cells that overexpress HRG-1. Cellular uptake of a fluorescent heme analogue is enhanced by HRG-1 in a V-ATPase-dependent manner. Our findings indicate that HRG-1 regulates V-ATPase activity, which is essential for endosomal acidification, heme binding, and receptor trafficking in mammalian cells. Thus, HRG-1 may facilitate tumor growth and cancer progression.